Document is current
Any future updates will be listed below
-
Authors
Maham, Syeda
Khan, Mudassir
Noor, Aleeha
Adnan, Fazal
Kakar, Salik Javed
Mian, Afsar Ali
Khan, Dilawar
-
Funding
Funding for this research was provided by:
Higher Education Commision, Pakistan (21–1826/SRGP/R&D/HEC/2018)
- License Information
-
More Information
Article History
Received: 23 March 2025
Accepted: 28 August 2025
First Online: 9 October 2025
Declarations
:
: All the experimental protocols were approved by National University of Sciences and Technology (NUST) institutional review board, and the certificate has been received for “Development of drug-able CRISPR/Cas9 for treating beta-Thalassemia and Sickle Cell Anemia”. All the experiments were performed in accordance with relevant guidelines and regulations. An informed consent for participation of the outcomes was obtained prior to performing any procedure.
: An informed consent for publication of the outcomes was obtained prior to performing any procedure.
: The authors declare no competing interests.
